Developing first-in-class therapies at the interface of inflammation, metabolism and immunity
Kynos therapeutics
Kynos is a clinical-stage biotech company developing novel small molecule inhibitors of kynurenine monooxygenase (KMO), as an innovative therapeutic approach in acute and chronic inflammation.
The history
Kynos launched in April 2022 as a spin-out from the University of Edinburgh.
Founded by Professors Damian Mole and Scott Webster, Kynos leverages a long history of research on KMO biology in acute inflammation, and a decade-long collaboration with GSK that optimised highly potent and selective KMO inhibitors
